Iron Deficiency and Anemia in Heart Failure: Clinical Applications for the Use of Intravenous Iron

This activity was originally broadcast in conjunction with the 2023 ASHP Midyear conference.

Program Description
Iron deficiency (ID) is a common comorbidity in patients with heart failure (HF) and may lead to anemia in some patients. ID is linked to increased risk and duration of hospitalization and is associated with an increased risk of mortality for those living with HF. Pharmacists must improve recognition of ID in patients with HF, preemptively identify risk factors, and recommend screening. Advances in the understanding of ID in HF coupled with the development and use of intravenous (IV) iron therapies have led to improvements in patient outcomes compared with oral iron. As central members of the care team for patients with HF, pharmacists should understand the clinical data and evolving guideline recommendations supporting the use of IV iron in patients with ID and HF. This program will specifically examine the role of health-system pharmacists in providing patient education on the risk of ID and anemia in HF, dosing regimens or potential adverse effects with IV iron formulations, and transitions of care.

Target audience: Health-system pharmacists

Type of activity: Application
Release date: December 18, 2023
Expiration date: December 18, 2024

Time to complete activity: 1.5 hours

Learner level: Foundational

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the association of iron deficiency (ID) and anemia with heart failure (HF), including onset, clinical presentation, and criteria for diagnosis
• Identify challenges that hinder the diagnosis and initiation of appropriate treatment for ID and anemia in HF
• Analyze current evidence and recommendations to guide treatment decisions for ID and anemia in HF
• Investigate strategies to individualize the management of patients with ID and anemia in HF

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-456-H01-P. The activity is available for CE credit through December 18, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Stormi E. Gale, PharmD, BCCP, BCPS, FHFSA

Ian B. Hollis, PharmD

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD, RPh; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms